Source link : https://www.newshealth.biz/health-news/fda-calls-astrazenecas-nsclc-trial-design-into-question/
AstraZeneca was taken to task last week by the US Food and Drug Administration’s (FDA’s) Oncology Drug Advisory Committee (ODAC) for failing to heed an agency request about the design of a durvalumab (Imfinzi) trial for non–small cell lung cancer (NSCLC). The trial in question, AEGEAN, investigated perioperative durvalumab for resectable NSCLC tumors across 802 […]
Author : News Health
Publish date : 2024-07-29 16:00:42
Copyright for syndicated content belongs to the linked Source.
Categories